$Centessa Pharmaceuticals (CNTA.US)$ and $Schrodinger (SDGR....
$Centessa Pharmaceuticals(CNTA.US$ and $Schrodinger(SDGR.US$ will collaborate to discover therapies targeting the Orexin-2 receptor for sleep disorders.
The agreement will give Centessa subsidiary Orexia Therapeutics access to Schrodinger's computing platform. The platform allows for high performance computing in order to accurately predict the effectiveness of the target of interest.
The terms require Orexia to handle preclinical research activities, clinical development, and commercialization of potential candidates.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
